2-DG Research – Lampidis Cancer Foundation

Latest Applications of 2-DG for Cancer and Alzheimer’s

by AJ Montpetit on June 5, 2024

You might have read a review article my colleagues and I wrote a few years ago titled, “The Wonders of 2-Deoxy-D-glucose.“ In the opening part of the review, we explainedour ideas as to why 2-DG was such a special molecule as follows:

“Through the eons of time, out of all possible configurations, nature has selected glucose not only as a vital source of energy to sustain life but also as the molecule whose structure supplies the appropriate elements required for a cell to grow and multiply. This understanding, at least in part, explains the profound effects that the analog of glucose, 2-deoxy-D-glucose (2-DG), has been shown to have on as common and widespread diseases as cancer, viral infection, aging-related morbidity, epilepsy, and others.”

So, it should come as no surprise to learn that recently, Alzheimer’s disease and ischemic stroke has been added to the ever-growing list of diseases where 2-DG is making an impact, as reported by the laboratory of Dr. Rajiv R. Ratan, MD PhD, CEO of the Burke Neurological Institute at Weill Cornell Medicine in the September 2023 issue of the journal Neuron titled: “2-Deoxyglucose drives plasticity via an adaptive ER stress-ATF4 pathway and elicits stroke recovery and Alzheimer's resilience.”

We are very pleased to report that Dr Ratan has graciously agreed for us to join forces to investigate how 2-DG, as well as other sugar analogs we’ve developed for cancer, can best be used to uncover mechanisms underlying Alzheimer’s disease.

We have recently been invited to submit a grant application by the Cure Alzheimer’s Fund with the goal of exploring 2-DG and the other glucose analogs to investigate how they may be developed to better treat Alzheimer’s patients.

By combining Dr Ratan’s expertise and leadership in treating neurological diseases and his close association with Dr. Li Gan – a leader in investigating Alzheimer’s disease and developing Alzheimer’s animal models – we are delighted to be able to add our insights on sugar analogs to this team of experts for the newfound application of 2-DG in
treating Alzheimer’s.

I am also pleased to announce that Dr Daniel Stanciu, founder of the MCS Foundation for Life and co-founder of MCS Formulas – a rising supplement company with a focus on providing supplements for cancer patients – has graciously and generously offered to donate 40,000 euros ($43,500 USD) to use the slow drip protocol we jointly developed to study its use in stage 4 cancer patients in India.

This donation and study will allow us to continue our collaboration with Arpan Talwar and Dr Mandeep Singh, co-founders of the Art of Healing Cancer – a unique institution integrating multiple treatment modalities from modern to traditional medicine and
applying them to late-stage cancer patients.

Our collaborations with this group have already yielded positive results in numerous cancer patients treated with our slow-drip delivery protocol of 2-DG, and the upcoming study will hopefully add to that success and further document the benefits that this remarkable sugar analog offers to late-stage cancer patients.

Additionally, G.ST-antivirals in Vienna, Austria, who we’ve worked closely with, announced recently that their nasal spray delivery of 2-DG for treating rhino-viral infections responsible for the common cold, successfully passed their Phase I clinical trial showing that it was well-tolerated and safe. Based on this result, they have been approved to move ahead for a Phase II trial to determine efficacy.

In my view, the science behind the use of 2-DG for ever-increasing medical applications is now so strong it is only a matter of time before this sugar analog will eventually be made available to the millions of patients that can benefit from it.

I am glad that those of you who follow our work are able to witness and share in our enthusiasm for its success to date and potential for the future.

Dr Theodore “Ted” Lampidis

2-DG Research Lampidis News

The Ever-Expanding Use of 2-DG to Fight Human Disease

by Lampidis News on September 23, 2023

Modern,Medical,Research,Laboratory:,Two,Scientists,Working,,Using,Digital,Tablet,

In a review article entitled the “Wonders of 2-Deoxy-D-glucose” (Xi H, Kurtoglu M, Lampidis TJ.. IUBMB Life. 2014 Feb;66(2):110-21), we wrote that it comes as no surprise that this sugar analog could have such profound and widespread effects on major diseases such as aging, cancer and viral infections because it mimics glucose which not only is a vital energy source but “provides the building blocks for a cell or virus to replicate”.

Now comes a new study that reports the effectiveness of 2-Deoxy-D-glucose (2-DG for short) in animal models of Alzheimer’s disease as well as cerebral stroke: 2-Deoxyglucose drives plasticity via an adaptive ER stress-ATF4 pathway and elicits stroke recovery and Alzheimer's resilience (Kumar A, Karuppagounder SS, Chen Y, Corona C, Kawaguchi R, Cheng Y, Balkaya M, Sagdullaev BT, Wen Z, Stuart C, Cho S, Ming GL, Tuvikene J, Timmusk T, Geschwind DH, Ratan RR Neuron. 2023 Jul 11:S0896-6273(23)).

In this study, the investigators report that 2-DG stimulates the expression of brain-derived neurotrophic factor (BDNF for short) which basically makes brain cells able to reverse the effects of injury as well as regrow.

These findings come on the heels of a recent case study in which it was demonstrated that the 2-DG slow-drip (metronomic) protocol we designed and is now being used in several different countries in stage four cancer patients, had a profoundly positive effect in a patient suffering from glioblastoma, an incurable form of brain cancer which kills more than 200,000 patients each year.

With the approval in 2021 by the Indian government for 2-DG to be used against SARS-CoV-2, the virus that causes COVID-19 when it was sweeping the country, another new step forward for the use of this unique sugar analog against viral diseases was taken.

Subsequently, it was reported that our findings of 2-DG’s effectiveness in causing ER stress could be applied to increasing the efficacy of immunotherapy as reported by Greco et al: Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid malignancies (Sci Transl Med. 2022 Jan 19;14(628)).

Thus, it is clear that the use of 2-DG continues to expand, which as we wrote in 2014, is not surprising based on its ability to mimic such an important natural sugar, glucose.

Although, due to its non-patentability, 2-DG has yet to be fully approved by the FDA for it to be available to the many more it can help, the science supporting it continues to be uncovered.

With your help in joining us to raise the funds required for it to successfully complete clinical trials, we remain hopeful that 2-DG will reach those that it can truly help in an ever-expandingrange of diseases.

2-DG Research Lampidis News Medical Research

Latest Developments in 2-DG Show Promise for Cancer and Anti-Viral Applications

by Dr. Ted Lampidis on February 22, 2023

Close up of lab assistant in uniform, with mask and rubber gloves holding test tube with blood sample while sitting on chair and typing on laptop. Selective focus on test tubes.

By Dr. Ted Lampidis

Most medical researchers never live long enough to realize that what they have accomplished has contributed to humanity in the form of a life-saving procedure, medical device, drug, or vaccine. Perhaps the best example of this is the Salk vaccine for the prevention of the catastrophic disease known as polio, which in the 1950s infected hundreds of thousands and either killed, permanently crippled or left millions fighting for their lives lying in iron lung machines.

Unfortunately, many of those scientists that first worked on uncovering the intricacies of how the immune system works or how a virus is able to infect a host cell – and all the pathways required to be activated and employed to produce more virus necessary for the Salk vaccine to be created – never lived long enough to see how their efforts ended up saving millions of lives.

So, I consider myself very fortunate to see that the sugar analog, 2-deoxy-D-glucose (2-DG for short) that I have been researching and developing for human use for the past 40 years, from my days as a post-Doc researcher at the Dana Farber Cancer Institute, is being used today to treat stage 4 cancer patients in a number of countries around the world.

2-DG is unique in that by mimicking glucose, it preferentially accumulates in cancer cells, and once inside the cell, it blocks the further use of glucose thereby shutting off a vital energy source as well as the material required for a cell to multiply. Similarly, it lowers the energy and shuts down the building blocks required for a viral-infected cell to produce more virus.

When I started my research, I had no idea that eventually this sugar analog known as 2-DG would be approved by the Indian government to be used to treat COVID patients. Although in retrospect, there have been several reports as early as the 1950s indicating increased glucose metabolism is a common trait among a wide variety of cells infected with different viral types.

The fact that 2-DG preferentially accumulates in cancer and viral-infected cells by exploiting a natural trait, common to both of these different cell types, sets it apart from other anti-cancer and anti-viral drugs that enter equally into cancer, normal, viral-infected and non-infected cells.

Thus, there is growing awareness of how unique and powerful a drug 2-DG is, and the increasing number of medical applications it has. In this regard, in a recent review written in collaboration with my dear departed colleague Dr. Enrique Mesri at the University of Miami, the science upon which 2-DG came to be used to treat COVID and other viral diseases is described.

In this review, we detail how our surprising findings that 2-DG kills select tumor types even when growing under normal oxygen levels, have been applied to inhibiting KSHV, the virus responsible for inducing Kapos’si Sarcoma the most prevalent cancer in AIDS patients. The mechanism uncovered was that 2-DG acting as a mannose analog interferes with a process known as n-linked glycosylation. This process involves the attachment of a string of sugars (oligosaccharides) to proteins to make a glycoproteins which then attach to the outside of a cell where they perform different functions.

When 2-DG interferes with this process, it induces a form of stress – referred to as “ER stress” – that leads to a shutting down of viral replication. This is in addition to the aforementioned action of 2-DG acting as a glucose analog and inhibiting the building blocks required for viral production. Thus, it appears that 2-DG has more than one way to block viral replication.

With regard to 2-DG interfering with glycosylation, it was recently announced that the Noble Prize in chemistry was awarded to Dr. Carolyn Beertozzi for her work in glycobiology where one of her breakthroughs was on the interference of glycosylation of cell surface glycoproteins to enhance immunotherapy.

This follows the recent publication in an issue of Science Translational Medicine, where it was shown that 2-DG was effective in enhancing CAR T-cell therapy by breaking down the glycosylation shield that surrounds tumors inhibiting the access of immunotherapy. Several of our lab’s publications were cited in this article for the role we played in uncovering 2-DG’s effects on glycosylation as it applies to cancer.

This recent data further strengthens the significance of our work on 2-DG, demonstrating that in addition to mimicking glucose and inhibiting glycolysis, as an analog of mannose, it interferes with glycosylation which can be used to enhance cancer treatment as well as potentially treat a number of viral diseases such as COVID, herpes and others.

Below are excerpts from a recent review (2021) on glycobiology and glycosylation highlighting the importance of the emerging new field of glyco-immunotherapy. “Cancer immunotherapy has revolutionized treatment and led to an unprecedented wave of immuno‐oncology research during the past two decades. …However, the challenge in the coming decade is to develop cancer immunotherapies that can more consistently treat various patients and cancer types…The role of aberrant glycosylation in this process, and how it influences tumor immunity and immunotherapy is beginning to emerge… We discuss these insights in the context of clinical findings and provide an outlook on modulating the regulation of glycosylation to offer new therapeutic opportunities. Finally, in the coming age of systems glycobiology, we highlight how emerging technologies in systems glycobiology are enabling deeper insights into cancer immuno‐oncology, helping identify novel drug targets and key biomarkers of cancer, and facilitating the rational design of glyco‐immunotherapies. These hold great promise clinically in the immuno‐oncology field.”

Based on the recent events described above, it appears that the science behind 2-DG justifies the title of a review that my students and I wrote several years ago – The Wonders of 2-Deoxy-D-glucose – which highlights some of the salient features of this truly remarkable sugar analog. From that review, the following excerpt summarizes our thoughts on why 2-DG is such an important molecule: “Through the eons of time, out of all possible combinations and configurations of hydrogen, carbon and oxygen, nature has selected glucose not only as a vital source of energy to sustain life but also as the molecule who’s structure supplies the appropriate elements required for a cell to grow and multiply. This understanding, at least in part, explains the profound effects that the analog of glucose, 2-deoxy-D-glucose, has been shown to have on as common and widespread diseases as cancer, viral infection, aging-related morbidity, epilepsy and others.”

2-DG Research Lampidis News Medical Research

Increased Glucose Uptake of Viral-infected Cells Suggests 2-DG Could Be Effective in the Fight Against COVID-19

by Lampidis News on April 15, 2020

From PET scan results to molecular biology data, it has long been known that increased glucose metabolism is a common trait of cancerous cells. More recently, however, viral-infected cells have also been found to increase their glucose uptake. In both cases, using carbon tracer experiments and mass spectrometry, glucose has been shown to be the molecule that provides the building blocks required to make more cancer cells and viral particles, respectively.

As an analog of glucose, 2-DG (2-deoxy-D-glucose) becomes a possible candidate for COVID-19 treatment by exploiting its preferential uptake in infected cells. 2-DG has also been shown to have anti-inflammatory effects that may benefit COVID-19 patients, especially in the latter phase of their disease. In a preliminary experiment completed on March 20, 2020, in the UK before the lab was closed in the national lockdown, 2-DG lowered the viral load by 1-2 logs in avian coronavirus infected cells in vitro at 3 and 10 mM.

Another advantage of 2-DG is its ability to block the replication of a variety of viral types by a number of different mechanisms which include the following:

Incorporating falsely into the structure of the viral capsid (head), leading to attenuation of its ability to become a fully infectious virus
Interfering with normal glycoprotein folding in the endoplasmic reticulum (ER) leads to ER stress blocking viral replication by activating the unfolded protein response and shutting down protein synthesis
By inhibiting glycolysis, 2-DG shuts off the building blocks required for a virus to replicate

Until today, however, there was no reliable data on how 2-DG would affect COVID-19. Using what is known as “in silico molecular modeling” (a non-cellular method which predicts how a drug will bind to its target and therefore inhibit its function), it has been shown that the structure of 2-DG fits into several of the binding sites that allow COVID-19 to attach as well as to replicate once it gets into a cell.

This is the first published report that directly examines the COVID-19 sites that 2-DG could have significant anti-viral activity on. It predicts that 2-DG will interfere with viral pathogenesis by binding what is known as its protease as well as its endoribonuclease. Each of these sites is required for proper viral replication and infectivity.

Moreover, the authors show that the docking of 2-DG with the main protease 3CLpro and NSP15 endoribonuclease of COVID-19 is significantly better than that of the standard anti-viral drugs lopinavir and favipiravir.

This recent publication together with the anti-viral activity of 2-DG previously reported in a number of different virus types, as well as via a number of different mechanisms by which it inhibits viral replication, adds further support to the call for 2-DG to be tested against COVID-19 live virus. We are aware of several such experiments currently taking place around the world – watch this space for further updates!

2-DG Research Lampidis News Medical Research

Data Supporting 2-DG as a Possible Treatment for COVID-19

by Lampidis News on March 26, 2020

The following is a review of the literature and evidence supporting the anti-viral properties of 2-DG, lending further credence to our hypothesis that it can be used as a possible treatment for COVID-19. We are in the process of putting together an international team of experts from the scientific community to accelerate this important work, and have applied to several organizations for grants to fund this research.

To donate to this cause

Click Here

Preliminary results: 1 experiment completed March 20, 2020 at The Pirbright Institute (UK) before lab closed in national lockdown, indicating 2-DG lowers viral load by 1-2 logs in avian coronavirus infected cells in vitro at 3 and 10 mM.

2-DG spray effective in blocking rhinovirus in vitro and an in vivo animal model. Gualdoni GA, et al, and Stöckl J. Proc Natl Acad Sci USA. Jul 24;115(30) (2018)

Triggering unfolded protein response by 2-deoxy-D-glucose inhibits porcine epidemic diarrhea virus propagation. Wang,Y, Li,JR, Sun, MX, Ni, B, Huan, C, Huang, L, Li, C, Fan, HJ, Ren, XF and Mao, X. Antiviral. Res. 2014 Jun 106:33-41, (2014)

Activation of the unfolded protein response by 2-deoxy-D-glucose inhibits Kaposi's sarcoma- associated herpes virus replication and gene expression. Leung HJ, Duran EM, Kurtoglu M, Andreansky S, Lampidis TJ, Mesri EA. Antimicrob Agents Chemother. 56(11):5794-803, (2012)

2-DG safe and well-tolerated in cancer patients treated with oral bolus once per day, for periods up to a year. Raez LE, et al, Lampidis TJ. Cancer Chemother Pharmacol. 71(2):523-30. (2013) Currently being used by > 20 stage 4 cancer patients delivered metronomically 1 gm/24-48 hr slow infusion (2x per week for 18 mths in 1 pt) with no serious side effects reported at this dose

Report that Kaposi's sarcoma herpes virus induces increased glucose metabolism in host infected cell, similar to what is known in tumor cells. This provides strong support for the selectivity of 2-DG to preferentially accumulate in viral-infected cells. Delgado, T., Carroll, P. A., Punjabi, A. S., Margineantu, D., et al. Proc. Natl. Acad. Sci. USA 107, 10696– 10701. (2010)

Under normoxia, 2-DG elicits cell death in select tumor types by interfering with N-linked glycosylation. Kurtoglu,M et al. Lampidis TJ. Mol Cancer Ther. 6(11):3049-58, (2007)

Anti-viral action of 2-DG in herpes simplex virus by altering glycoproteins required for penetration and infectivity. Spivak, JG, Prusof, WH, Tritton, TR Virology, 123 (1) 123-138, (1982)

2-DG blocks infectious Rous Sarcoma virus replication by 100 fold but total replication only 3 fold. Unglycosylated envelope protein accounts for non-infectious virion. Stohrer, R and Hunter, E J Virol. 1979 32(2): 412–419, (1979)

2-DG incorporates fraudulently into oligosaccharide chain mannose disrupting influenza viral glycoprotein capsid formation. Datema, R and Schwarz, R. T. Eur J Biochem 184,113-123 (1979)

2‐DG blocks infectious Semliki Forest virus production in chick embryo cells ivia interference with glycosylation of virus‐specific glycoproteins. Schmidt, M. F. G., Schwarz, R. T. & Scholtissek, C. Eur Biochem 49: 237, (1974)

PLEASE NOTE: As with any new treatment, safety is the first consideration and that’s exactly why FDA approved clinical trials start with a Phase I trial – to ensure safety in humans and to determine the maximum tolerated dose (MTD). So before we have people going out and using 2-DG as a possible treatment for COVID-19, we need to make sure it’s safe, using the steps that all drugs take in getting to the general public.

2-DG Research

2-DG and Coronavirus?

by Lampidis News on March 16, 2020

Abstract 3d cells of human or animal. Science concept

We have been developing 2-deoxy-D-glucose (2-DG), an analog of glucose, as a non-toxic anti-cancer agent and in an FDA-approved Phase I clinical trial, found it to be safe in patients.

In the trial, 2-DG was used for its inhibitory effects on glycolysis, thereby shutting down increased glucose metabolism, a universal trait of many different cancer types. The shutdown of glycolysis produces energy stress on the cancer cell which provides a window of selectivity since tumor cells require more glucose than normal cells.

However, 2-DG also mimics another natural sugar, mannose, which produces another kind of stress in the cancer cell referred to as endoplasmic reticulum (ER) stress – inducing an unfolded protein response (UPR), that in turn shuts down further protein synthesis in order to alleviate this kind of stress.

Since many viruses use ER to become fully formed and infective, they have developed a means to overcome (circumvent) UPR-mediated blockage of protein synthesis, which allows them to be produced.

We reasoned that with pre- or simultaneous treatment of virally-infected cells with 2-DG, activating the UPR would shut down protein synthesis, thereby blocking viral replication. We have previously reported that our idea worked in a herpes virus known to cause cancer in AIDS patients. Subsequent publications showed that 2-DG blocks viruses that either cause lethal hemorrhagic fever in pigs or the common cold in humans.

In the latter report, investigators used a nasal spray of 2-DG to block rhinovirus replication in animal models. Since coronavirus causes similar symptoms, it would be important to test 2-DG spray in preclinical models of coronavirus. If it worked, 2-DG nasal spray could be used by humans to not only treat those infected by coronavirus, but as a prophylactic to block viral infection spread.

In this way, what is known as “herd immunity” could be achieved similar to what vaccines such as the polio vaccine have done to wipe out the disease by eliminating susceptible individuals thereby blocking further infectivity.

The dual activity of 2-DG of inhibiting glycolysis and modulating protein synthesis, offers the possibility of blocking viral replication by more than one mechanism. In the rhino virus model mentioned above, the investigators showed that inhibiting glycolysis is how 2-DG blocks viral replication. Remodeling of glucose metabolism toward a more glycolytic one is emerging as a common trait of virally-infected cells.

Similarly, cancer cells undergo a shift from oxidative phosphorylation to glycolysis in order to meet the demands of rapid growth (known as the "Warburg effect"). In other words, viruses, as well as cancer cells, use glucose not only as a vital energy source but also as the building block for further production, which has been demonstrated with carbon 13 tracer experiments and mass spectrometry.

Thus, by interfering with the increased glucose metabolism of virally-infected cells, 2-DG offers a possibility of using a proven, non-toxic, inexpensive and rapid means of treating viral outbreaks such as that of coronavirus.

Having 20+ years of experience in investigating the mechanisms by which 2-DG interferes with glucose metabolism, and interacting with investigators that are experts in herpes viral replication here at the University of Miami, and those developing 2-DG nasal spray for the common cold at the Vienna Medical Institute in Austria, and more recently with an expert in coronaviral replication in England, I believe we may have enough expertise to make an impact on this current world-wide pandemic.

Any resources that readers of this blog can contribute will be donated directly to this immediate cause.

2-DG Research LCF Blog

2-DG Continues to Show Highly Promising Results in Late-stage Cancer Patients

by Dr. Ted Lampidis on October 16, 2019

Since 2-DG became available in Germany in 2018, The Lampidis Cancer Foundation has been actively collaborating with participating doctors and clinics worldwide on implementing protocols for metronomic (slow-release) delivery of patient grade 2-DG for compassionate use cancer treatment to patients with highly promising preliminary results across different cancer types.

Patient A, female, 40-50 years, (Spain) – Stage 4, Endometrial Cancer: After intensive treatment where metronomic 2-DG was included, reduction of tumor markers from 240 to 80 and destruction of at least half of the 14 lung nodules were reported.
Patient B, femaie, 50 years, (Romania) – Stage 3, Ovarian Cancer: Advanced cancer with no treatment before beginning M2-DG. Accepted 10 X lower than normal chemotherapy (cisplatin + paclitaxel) with M2-DG and metformin. In complete remission.
Patient C, femaie, Glioblastoma (Spain): Patient’s condition has improved since using a combination of M2-DG + Salinomycin. The tumor is stable and showing signs of regression.

These remarkable, albeit anecdotal results are based on Dr Lampidis’ groundbreaking research using a false sugar (2-deoxy-D-glucose or 2-DG) to literally starve the treatment-resistant, slow replicating cancer cells found at the core of all tumors, which require glucose to survive in a non-oxygen (hypoxic) environment. In vivo and in vitro studies successfully demonstrated that 2-DG is able to kill the most resistant cancer cell populations found within every solid tumor, which led to the successful completion of a FDA-approved Phase 1 clinical trial. Subsequent experiments in the lab demonstrated that using a metronomic (slow-release) pump to deliver 2-DG at continual, low level doses avoids both an insulin response and liver absorption whilst increasing efficacy of significant tumor volume control. Although the preliminary clinical data from current human use studies is still at an anecdotal stage, it is encouraging to know that several patients receiving metronomic 2-DG treatment via pump through a central venous catheter (PICC line) are reporting excellent tolerance as well as a reduction in the size and/or elimination of their respective tumor types.

HOW YOU CAN HELP: We are currently lobbying the FDA to gain approval for metronomic 2-DG treatment to be administered in the US under the Right to Try Act.

If you are an oncologist or integrative medicine physician interested in using this treatment protocol on your patients, contact us here.

If you are a cancer patient or caregiver interested in learning more about this treatment protocol, contact us here.

If you are interested in supporting our mission to deliver a low cost, non-toxic cancer treatment to millions of patients worldwide, donate here.

2-DG Research LCF Blog

Developing a Non-toxic Approach to Treating Cancer

by Lampidis News on May 9, 2019

Combining non-toxic glycolytic inhibitors with non-toxic antibiotics

Although it has long been known that the anti-oxidant properties of vitamin C may be linked to its purported anti-cancer properties, more recently the blockage of glucose uptake by vitamin C appears to be another important anti-cancer property of this widely used and non-toxic agent.

Importantly, in this recent report published in Oncotarget, the investigators show that combining vitamin C with the widely used antibiotic, doxycycline, which affects mitochondrial function, yields potent toxic effects across a broad range of tumor types.

We have previously shown similar wide-reaching anti-cancer activity with the glycolytic inhibitor, 2-DG, when used in cancer cells that have their mitochondrial function compromised either by exposure to low oxygen (hypoxia), or when co-treated with a mitochondrial agent, or when harboring a genetic defect in their mitochondrial DNA.

Interestingly, in this latest report, the authors suggest vitamin C to be more potent than 2-DG when combined with doxycycline. It would appear, however, if this strategy is applied to humans, then the benefits of the known selective uptake of 2-DG in cancer versus normal surrounding tissue (supported by the results of millions of PET scans) would make 2-DG a more cancer-specific agent to combine with doxycycline than vitamin C.

Overall, this recent publication further supports the continued development and investigation of combinations and strategies aimed at how to best use 2-DG to exploit increased glucose uptake and metabolism, which is a universal trait of cancer.

Our groundbreaking cancer research relies largely on philanthropy to keep moving forward. Please consider donating to our cause. Our goal is to raise $300,000/year to conduct the necessary research to bring our 2-DG treatment protocol through the relevant clinical trials in order to make it available to patients worldwide. We would appreciate your help by donating using the link above.

2-DG Research Government

Further Evidence that 2-DG Inhibits Aggressive Breast Cancer Cells

by Lampidis News on March 18, 2019

In a recent publication titled 2-Deoxy-D-Glucose Inhibits Aggressive Triple-negative Breast Cancer Cells By Targeting Glycolysis And The Cancer Stem Cell Phenotype – a research group in Ireland, headed by Dr. Lorraine Driscoll, showed that triple-negative breast cancer (TNBC) cells which are particularly resistant to conventional treatment in patients are sensitive to 2-DG. The study compares a particularly aggressive strain of TNBC to its less aggressive parental type. It shows that the more aggressive strain has in vitro characteristics (migration, invasion, and resistance to anoikis – a form of programmed cell death) of being metastatic. Results indicate that all three of these metastatic traits can be inhibited by 2-DG based on differences in the metabolism of these two TNBC lines.

However, the doses of 2-DG used in these experiments are 7.5 to 15 times greater than what we have previously shown can be achieved in patients when taking 2-DG orally once per day. Moreover, if used in patients, the doses in this study are at concentration levels where liver adsorption, as well as insulin induction, would redirect 2-DG into liver, fat and muscle cells and away from tumor sites.

This further supports the use of metronomic 2-DG (i.e., delivered via a slow-release pump) as a viable means of delivering 2-DG at low enough doses that will not induce liver adsorption and/or induction of an insulin response. Based on the millions of PET scans conducted to date, it is known that low dose 2-DG does preferentially accumulate in tumor versus normal cells. These results are now explained by more recent findings demonstrating that the very genes that are driving cancer (oncogenes) are found to also be responsible for increased glucose uptake and metabolism, justifying labeling 2-DG as a universal treatment for cancer. Thus, continuous slow-infusion of 2-DG will effectively accumulate in tumor cells and eventually reach a concentration that will be preferentially toxic to cancer versus normal cells.

We are currently exploring opportunities with the US Food & Drug Administration to make our metronomic 2-DG treatment protocol available to Stage 3 and 4 cancer patients under the FDA’s “Compassionate Use” designation. Watch this space for further updates.

Our academic research relies largely on philanthropy to keep moving forward. Please consider donating to our cause. Our goal is to raise $300,000/year to provide the necessary research to bring our 2-DG treatment protocol through the relevant clinical trials in order to make it available to patients worldwide. We would appreciate your help by donating using the link above.

2-DG Research LCF Blog

More Patients Reporting Encouraging Results Using Metronomic 2-DG in Fight Against Cancer

by Lampidis News on February 7, 2019

Ethnic young adult female cancer patient sipping tea

As reported in September, the Lampidis Cancer Foundation, along with the MCS Foundation for Life, has been actively collaborating with clinics worldwide on implementing protocols using 2-DG for patients who have failed standard treatment. The following patient updates have been received as of the end of January.

Patient A, male, 25 years, Ewing Sarcoma (grade 3): Prior to and after surgery and radiation therapy, metronomic 2-DG was administered, and there has been no sign or evidence of recurrence. It has been applied with other metabolic treatments and oncothermia.

Patient B, female, Ovarian Cancer (stage 4 with spleen and liver metastasis, and ascites): Metronomic 2-DG was administered after each session of low-dose chemotherapy (IPT) for 2 months. After treatment, there has been no sign or evidence of recurrence.

Patient C, male, Maxillary Carcinoma (stage 4, multiple metastasis including the brain, liver, bones, eye): This patient could not maintain chemo (Capecitabine and Irinotecan) due to the side-effects and continuous growth of tumors. After administering metronomic 2-DG, he is improving while some tumors are shrinking, including those in the eye.

One of the physicians reporting on the first two patients commented: “Although I am currently unable to quantify the actual contribution of 2-DG to these results, I am convinced it is having a positive impact. Furthermore, these results are highly unusual, as inoperable pancreatic cancer and grade 3 sarcomas are extremely aggressive.”

Since these stage 3 and 4 patients are concurrently receiving other treatments in addition to 2-DG, the data must be considered anecdotal. Nevertheless, as this is the first time patients have been treated with our laboratory-tested delivery method, it is very encouraging to know that excellent tolerance as well as reductions in the size of their respective tumor types and markers is being reported.

We will continue to report on patient outcomes from around the world as we receive them.

Our academic research relies largely on philanthropy to keep moving forward. Please consider donating to our cause. Our goal is to raise $300,000/year to provide the necessary research to bring this treatment protocol through the relevant clinical trials in order to make it available to patients worldwide. We would appreciate your help by donating using the link above.